EUCTR2016-002184-34-DK进行中（未招募）1 期
Phase II trial: uPAR-PET/CT in Radium-223-dichloride treatment of patients with metastatic castration-resistant prostate cancer
Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine & PET0 个研究点目标入组 43 人开始时间: 2016年8月17日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 43
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •- Metastatic castration resistant prostate cancer
- •- Approved to receive Radium-223 therapy
- •- Age = 18 years
- •- Written and oral consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 33
排除标准
- •- Lack of communication skills, including inability to understand study protocol
- •- Other known malignant disease
- •- Severe claustrophobia
- •- Known allergy towards the IMP
- •- If a participant exhibits allergic reaction to the IMP, the participant will be excluded from further participation in the study
研究者
相似试验
进行中（未招募）
1 期
uPAR PET/CT og FDG PET/CT til præoperativ stadieinddeling af patienter med nydiagnosticeret Gynækologisk Kræftgynecological cancers:Vulvar cancerendometrial cancer (uterine cancer)cervical cancerovarian cancerMedDRA version: 20.0Level: LLTClassification code 10007107Term: Cancer of ovarySystem Organ Class: 100000021045MedDRA version: 20.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 100000020935MedDRA version: 20.0Level: LLTClassification code 10047743Term: Vulval cancer NOSSystem Organ Class: 100000021101MedDRA version: 20.0Level: LLTClassification code 10007063Term: Cancer of endometriumSystem Organ Class: 100000021008MedDRA version: 20.0Level: LLTClassification code 10008229Term: Cervical cancerSystem Organ Class: 100000020977EUCTR2016-004638-99-DKRigshospitalet, Department of Clinical Physiology, Nuclear Medicine and PET350
进行中（未招募）
1 期
Phase II trial: uPAR PET/CT and FDG PET/MRI for determining lymph node metastases in patients with bladder cancerrinary bladder cancerMedDRA version: 19.0Level: LLTClassification code 10005004Term: Bladder cancer NOSSystem Organ Class: 100000004864EUCTR2016-001026-33-DKRigshospitalet, Department of Clinical Physiology, Nuclear Medicine and PET40
终止
2 期
uPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate CancerProstate Cancer MetastaticBone MetastasesNCT02964988Rigshospitalet, Denmark17
进行中（未招募）
1 期
uPAR-PET/CT for prognostication in head- and neck cancerHead and neck cancerMedDRA version: 19.0Level: HLTClassification code 10026660Term: Malignant oral cavity neoplasmsSystem Organ Class: 100000004856MedDRA version: 19.0Level: HLTClassification code 10028801Term: Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecifiedSystem Organ Class: 100000004864MedDRA version: 19.0Level: HLTClassification code 10023826Term: Laryngeal neoplasms malignantSystem Organ Class: 100000004864EUCTR2016-002082-65-DKAndreas Kjaer
进行中（未招募）
1 期
uPAR-PET/MRI in patients with prostate cancer for evaluation of tumor aggressivenessProstate cancerEUCTR2017-002276-37-DKRigshospitalet, Department of Clinical Physiology, Nuclear Medicine & PET52